The Center for HIV-Related Malignancies at Roswell Park Cancer Institute (RPCI) is the main treatment center for patients with AIDS-associated malignancies in Western New York. Under the direction of Dr. Zale Bernstein, the Center has had a rapid increase in patient referrals during the past two years. This, combined with Dr. Bernstein's commitment to protocol development and implementation has resulted in outstanding accrual of patients to both Institute and multi-institutional clinical trials, on par and in some instances exceeding accrual to protocols at more nationally prominent centers. In addition, two phase I clinical trials with biologic response modifiers have been completed within the past year. An extensive laboratory program of lymphocyte biology has been developed by Dr. Michael Caligiuri at RPCI that focuses on cytokine and cytokine receptor expression, as well as the characterization of human lymphomagenesis in the severe combined immune deficient mouse. This work has been translated into a number of Phase I and Phase II clinical trials, one of which has been completed by Dr. Bernstein in AIDS malignancy and is now being developed by the CALGB for a Phase II cooperative study. The Institute also has outstanding expertise in Flow Cytometry, a core facility that has been vital to the clinical and laboratory work of Drs. Bernstein and Caligiuri, respectively. With excellent patient accrual to clinical protocols in AIDS malignancies, strong data management and protocol support, and a continual source of laboratory based ideas for immune modulation using biologic modifiers for therapy of immune deficiency, RPCI has assembled a strong team of investigators who are likely to provide unique laboratory resources for correlative studies, substantial innovation in the design of clinical trials and patient accrual for rapid completion of such trials within the AIDS Malignancies Clinical Trials Consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA070079-04
Application #
2748844
Study Section
Special Emphasis Panel (SRC (09))
Program Officer
Wu, Roy S
Project Start
1995-09-30
Project End
1999-07-31
Budget Start
1998-08-07
Budget End
1999-07-31
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lin, Lan; Lee, Jeannette Y; Kaplan, Lawrence D et al. (2009) Effects of chemotherapy in AIDS-associated non-Hodgkin's lymphoma on Kaposi's sarcoma herpesvirus DNA in blood. J Clin Oncol 27:2496-502
Brinker, Brett T; Krown, Susan E; Lee, Jeannette Y et al. (2008) Phase 1/2 trial of BMS-275291 in patients with human immunodeficiency virus-related Kaposi sarcoma: a multicenter trial of the AIDS Malignancy Consortium. Cancer 112:1083-8
Dezube, Bruce J; Krown, Susan E; Lee, Jeannette Y et al. (2006) Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol 24:1389-94
Shah, Manisha H; Freud, Aharon G; Benson Jr, Don M et al. (2006) A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 12:3993-6
Kaplan, Lawrence D; Lee, Jeannette Y; Ambinder, Richard F et al. (2005) Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 106:1538-43
Noy, Ariela; Scadden, David T; Lee, Jeannette et al. (2005) Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol 23:990-8
Shah, Manisha H; Porcu, Pierluigi; Mallery, Susan R et al. (2003) AIDS-associated malignancies. Cancer Chemother Biol Response Modif 21:717-46
Miles, Steven A; Dezube, Bruce J; Lee, Jeannette Y et al. (2002) Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 16:421-9
Shah, Manisha H; Porcu, Pierluigi; Mallery, Susan R et al. (2002) AIDS-associated malignancies. Cancer Chemother Biol Response Modif 20:633-64
Khatri, V P; Baiocchi, R A; Bernstein, Z P et al. (1997) Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 3 Suppl 1:S129-36